Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CCOVW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-MMAU (DAR4)
|
|||||
| Synonyms |
T-mavg-MMAU
Click to Show/Hide
|
|||||
| Organization |
Janssen Pharmaceuticals, Spring House, Pennsylvania.; Glykos Finland Oy, Helsinki, Finland.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Glucuronyl-monomethyl-auristatin E (MMAU)
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Val-Ser (beta-Glc) cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||